This is an aggregated industry headline. Read the full story at BioPharma Dive →
Alnylam plunges as earnings deliver 'one-two punch'
The RNA-focused biotech shed 30% of its market value - or close to $12 billion - amid growing investor concerns about its main drug business.
By BioPharma Dive
· Jul 30, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor X…
The WeekFierceBiotech ↗
Whether it's looming tariff threats or the rise of China, you need a truly global view to navigate today's bio…
The WeekBriefing
AbbVie’s Skyrizi generated $5.55 billion in second-quarter sales, nearly matching Humira’s best quarter. The r…